Moderna and CEPI expand collab to include Bundibugyo ebolavirus vaccine

Cambridge, USA-based mRNA vaccines company Moderna today announced an expanded collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI) to advance the development of a potential vaccine against Bundibugyo ebolavirus (BDBV), a cause of Ebola virus disease for which there are currently no licensed vaccines indicated.